Andrew H. Ko, MD

Professor of Medicine and Associate Chief of the Division of Hematology/Oncology

University of California, San Francisco

Published Articles (1)

Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment

September 2, 2026

A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.